Brought to you by 
Novimmune gets CHF58mm in Series B round; later adds tranches, bringing total to CHF200.5mm
30 Oct 2017
Executive Summary
Novimmune (monoclonal antibodies for immune-related conditions and inflammation) raised CHF58mm ($46mm) through its Series B private placement that was led by new investor BZ Bank. Another new buyer, Pictet Private Equity Investors, was joined by existing backers Lombard Odier Darier Hentsch, Novartis Venture Fund, and Aravis Venture.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novimmune gets CHF58mm in Series B round; later adds tranches, bringing total to CHF200.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice